



5th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 23-24, 2024 • Boston, MA

Saturday, March 23

8:00 - 8:15

INTRODUCTION AND WELCOME

8:15 - 9:35

CLINICAL UPDATES ON CAR T CELLS

CHAIRS: *Jesus San Miguel and Krina Patel*

8:15 - 8:25	Ide-cel: latest data and ongoing trials	Paula Rodriguez-Otero
8:25 - 8:35	Cilta-cel: latest data and ongoing trials	Jesus Berdeja
8:35 - 8:45	Real world outcomes with CAR T cells for MM	Surbhi Sidana
8:45 - 8:55	Update on GPRC5D CAR T cells	Omar Nadeem
8:55 - 9:35	Discussion	Session faculty + Yi Lin

9:35 - 10:55

CLINICAL UPDATES ON BISPECIFIC ABS/TCE'S

CHAIRS: *Philippe Moreau and Hermann Einsele*

9:35 - 9:45	Teclistamab and Elranatamab: latest data and ongoing trials	Ajay Nooka
9:45 - 9:55	Talquetamab and Forimtamig: latest data and ongoing trials	Simon Harrison
9:55 - 10:05	The next bispecifics: Linvoseltamab, Alnuctamab, ABBV-383, Cevostamab	Suzanne Trudel
10:05 - 10:15	Combining bispecifics with monoclonal Abs, IMiDs, and each other	Yael Cohen
10:15 - 10:55	Discussion	Session faculty + Emma Searle

10:55 - 11:25

BREAK

11:25 - 12:45	HOW TO USE T CELL-DIRECTED THERAPIES TODAY AND IN THE FUTURE CHAIRS: <i>Kenneth Anderson and Marivi Mateos</i>	
11:25 - 11:35	What is optimal duration of therapy for bispecifics?	Niels van de Donk
11:35 - 11:45	Sequencing CAR T cells and bispecifics for relapsed/refractory myeloma	Ajai Chari
11:45 - 11:55	How should we use T cell therapies in frontline and maintenance?	Luciano Costa
11:55 - 12:05	T cell therapies for smoldering myeloma	Irene Ghobrial
12:05 - 12:45	Discussion	Session faculty + Sagar Lonial
12:45 - 1:45	LUNCH	
1:45 - 3:15	NOVEL THERAPEUTIC APPROACHES AND TARGETS CHAIRS: <i>Sonja Zweegman and Eric Smith</i>	
1:45 - 1:55	Update on rapid manufacturing CAR T cell products	Shambavi Richard
1:55 - 2:05	Dual antigen-targeted CAR T cells and trispecific antibodies	Sham Mailankody
2:05 - 2:15	NK cell-based CAR and bispecific approaches	Binod Dhakal
2:15 - 2:25	Targeting CD229 for myeloma therapy	Tim Luetkens
2:25 - 2:35	Redirecting T cells against SLAMF7 and ROR2	Sophia Danhof
2:35 - 3:15	Discussion	Session faculty + Sundar Jagannath
3:15 - 3:35	BREAK	
3:35 - 5:00	MANAGING TOXICITIES OF T CELL DIRECTED THERAPIES CHAIRS: <i>Heinz Ludwig and Pieter Sonneveld</i>	
3:35 - 3:45	Preventing infections after CAR T cell and bispecific Ab therapy	Noopur Raje
3:45 - 3:55	Immune effector cell-associated hematotoxicity	Kai Rejeski
3:55 - 4:05	Cardiac toxicity of CAR T cell therapy	Sarju Ganatra
4:05 - 4:15	Neurotoxicity associated with BCMA-targeted T cell therapies	Julianne Gust
4:15 - 5:00	Discussion	Session faculty + Aurore Perrot

Sunday, March 24, 2023

8:00 - 8:05	WELCOME	
8:05 - 8:35	PLENARY TALK Structure and function of novel bispecific chimeric T cell receptors	Stanley Riddell
8:35 - 10:05	UNDERSTANDING RESISTANCE TO IMMUNE THERAPIES CHAIRS: <i>Mehmet Samur and Marta Chesi</i>	
8:35 - 8:45	Mechanisms of antigen escape after T cell-redirecting therapies	Paola Neri
8:45 - 8:55	Using multi-omics to identify biomarkers of response to CAR T cell therapy	Maximilian Merz
8:55 - 9:05	Spatial profiling to interrogate the microenvironment	Madhav Dhodapkar
9:05 - 9:15	Using circulating tumor DNA to predict response or resistance	Hitomi Hosoya
9:15 - 9:25	Preclinical models to predict immune evasion	Jose Martinez-Climent
9:25 - 10:05	Discussion	Session faculty + Adam Cohen
10:05 - 10:30	BREAK	
10:30 - 11:50	NOVEL APPROACHES TO IMPROVE T CELL THERAPIES CHAIRS: <i>Ivan Borrello and Samir Parekh</i>	
10:30 - 10:40	Disrupting Blimp-1 to enhance CAR T cell therapy	Carlos Fernandez de Larrea
10:40 - 10:50	Update on genome-editing techniques	Michael Hudecek
10:50 - 11:00	In situ PEGylation to reduce CAR T cell-associated toxicities	Michael Mitchell
11:00 - 11:10	Clutch control: changing speed and direction of CAR T cell therapies	Carl Novina
11:10 - 11:50	Discussion	Session faculty + Nizar Bahlis
11:50 - 1:00	LUNCH	
1:00 - 2:00	CURRENT QUESTIONS IN IMMUNE EFFECTOR CELL THERAPIES FOR MM CHAIRS: <i>Charlotte Palwyn and Shaji Kumar</i>	
1:00 - 1:10	Should we profile T cell fitness prior to T cell-redirecting therapy?	Bruno Paiva
1:10-1:20	Should we profile antigen expression/mutation status prior to T cell-redirecting therapy?	Leo Rasche
1:20-1:30	Can vaccines or novel checkpoint inhibitors enhance response to CARTs or BsAbs?	David Avigan
1:30-2:00	Discussion	Session faculty + Kwee Yong

2:00 - 3:15	WORKSHOP ON EXPANDING ACCESS TO T CELL THERAPIES	
	CHAIRS: <i>Nikhil Munshi and Amrita Krishnan</i>	
2:00-2:10	Improving clinical trial enrollment of underrepresented populations	Monique Hartley-Brown
2:10-2:20	Improving real-world access to T cell therapies in the US	Ben Derman
2:20-2:30	Challenges associated with T cell therapies in South America	Vania Hungria
2:30-2:40	Balancing the budget: CAR-T cell and bispecific use	Vincent Rajkumar
2:40-3:15	Discussion	Session faculty + Philippe Moreau
3:15-3:30	CONCLUSION AND WRAP-UP	

Thank you to our sponsors

TITANIUM



SILVER

